Pharmetheus offers consulting services focused on the application of quantitative approaches to support drug development decisions.
Pharmetheus closely monitors the developing COVID-19 pandemic. We are continuing to run our operations largely as normal with close to full capacity. For some time now we have taken measures to ensure the safety and health of our employees and collaborators. These measures have included restrictive travel policies, enabling remote working and the provision of regular updates on our measures taken as a result of the dynamic and emerging situation.
We remain fully committed to deliver and satisfy the needs of our clients – thank you for your continued partnership.
Peter Milligan, CEO
Marie Sandström, COO
On behalf of the Pharmetheus Team
Latest news from Pharmetheus
New service: Quantitative Systems Pharmacology (QSP)
Congratulations Prof. Andrew Hooker!
Welcome Henrik Hellerstedt!
Covid-19 Pharmacology Resource
We have now joined the COVID-19 Pharmacology Resource Center. Conquering COVID-19 with clinical pharmacology, innovation, and collaboration.
More information available at the Covid-19 Pharmacology Resource web page
Pharmetheus Approach to COVID-19 related challenges in clinical trial conduct
Pharmetheus is currently working with a number of clients to address the impact of the current COVID-19 epidemic to their ongoing clinical drug development programs. We would like to share our high level approach with the community at large. We see the current situation as both a challenge to our industry/sector but also an opportunity for appropriate and quantitative approaches to mitigate upon these challenges. We believe there are "fit for purpose" options for a broad range of plausible scenarios in clinical trial conduct that have emerged or could emerge.
See our approach
Welcome Julie Janssen and Anna Pousette!
We are very happy to welcome two new team members, Julie Janssen, MIDD consultant, and Anna Pousette, Contracts Manager. Julie's research experience includes the application of pharmacometrics in the clinical setting, chemotherapy and targeted therapies, as well as special patient populations (e.g. pediatrics and pregnancy). Julie is based in the Netherlands. See Julie's bio here. Anna has long experience of project coordination and procurement. Anna will work from our Uppsala office in Sweden. See Anna's bio here.
Open Systems Pharmacology publication
PBPK training at WCoP2020
Going to WCoP 2020 in Cape Town?
Join the 1-day hands-on workshop "Open source PBPK modelling with the OSPSuite (PK-Sim® & MoBi®) for MIDD" hosted by Pharmetheus and Pharmacometrics Africa.
Read more and register here.
Register soon, only limited seats available!
Welcome Marie Olsson!
Welcome Siv Jönsson!
It is with great pleasure that we welcome Siv Jönsson to our team! Siv has been working in the pharmacokinetic, pharmacodynamic and pharmacometric areas in the pharmaceutical industry for a total of 5 years (Kabi Pharmacia, AstraZeneca), as a regulatory assessor at the Swedish Medical Products Agency for 9 years, and spent +10 years in academia as a senior lecturer and researcher dealing with methodological and applied pharmacometric projects. See her bio here.
We are active in the biosimilar area
Mechanism based pharmacometric analysis can be a powerful tool in the development of biosimilar drugs. Pharmetheus recently supported a client with evaluating the impact of study design and expected product differences on the power to demonstrate PK and PD similarity. Find out more in a recent paper by Ari Brekkan et al. AAPS J. 2019 Jul 8;21(5):85.
Welcome Ola Caster!
We are happy to welcome Ola Caster in our growing enabler team. Ola comes most recently from a position as a Senior Researcher at the Uppsala Monitoring Centre, where he worked primarily with methods for adverse effect detection and benefit-risk assessment in the post-marketing setting. He has more than ten years of experience from research in statistics and data science, including a PhD in Computer and Systems Sciences. See Ola's bio here.